Skip to main content

Table 5 Biochemical features during follow-up

From: Natural history of non-lethal Raine syndrome during childhood

 Case ICase IICase V
Age12 ys 6 mo13 ys 7 mo14 ys4 mo1 y 9 mo2 mo7 ys and 3 mo
Pre-therapyAt the end of the therapyaAt the end of follow-upPre-therapyAt the end of follow-upPre-therapyAt the end of follow-up
Calcium9.6 mg/dl
(nv 8.8–10.8)
9.8 mg/dl
(nv 8.8–10.8)
9.7 mg/dl
(nv 8.8–10.8)
10 mg/dl
(nv 8.8–10.8)
10.1 mg/dl
(nv 8.8–10.8)
1.92 mmol/L
(nv 2.20–2.79)
2.51 mmol/L
(nv 2.20–2.79)
Phosphorus2.6 mg/dl
(nv 4–7)
2.2 mg/dl
(nv 4–7)
2.6 mg/dl
(nv 4–7)
2.2 mg/dl
(nv 4–7)
2.1 mg/dl
(nv 4–7)
0.75 mmol/L
(nv 1.36–2.26)
0.73 mmol/L
(nv 1.36–2.26)
ALP555 U/L
(nv 140–400)
611 U/L
(nv 140–400)
419 U/L
(nv 140–400)
805 U/L
(nv 140–400)
487 U/L
(nv 140–400)
5605 IU/L
(nv 187–1197)
3874 IU/L
(nv 187–1197)
PTH79 pg/ml
(nv 15–65)
104 g/ml
(nv 15–65)
74 pg/ml
(nv 15–65)
71 pg/ml
(nv 15–65)
64 pg/ml
(nv 15–65)
72 pmol/L
(nv 1.1–6.9)
24 pmol/L
(nv 1.1–6.9)
25OHD39.2 ng/ml
(nv > 30)
35.2 ng/ml
(nv > 30)
39.2 ng/ml
(nv > 30)
57.9 ng/ml
(nv > 30)
51.2 ng/ml
(nv > 30)
<  40 nmol/L
(nv > 50 nmol/L)
17 nmol/L
(nv > 50 nmol/L)
TRP%NA66NA767372NA
FGF23NANANANANA157 RU/ml
(nv 0–100)
NA
CaU/CrU
(<  3 ys:; nv < 0.5
> 3 ys: nv < 0.39)
0.220.090.120.0260.10NormalNormal
Therapy with oral phospate saltyesnoyesyes
Therapy with oral alfacalcidiolnonoyesyes
Supplementation with oral cholecalciferolyesyesyesyesyes
  1. ALP alkaline phosphatase; CaU/CrU urine calcium to creatinine ratio; FGF23 fibroblast growth factor 23; Mo months; NA not available; NV normal value; PTH parathormone; TRP tubular reabsorption of phosphate; 25OHD 25-Hydroxy Vitamin D; ys years; alast measurements before stopping the therapy with phosphate salts